The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer

被引:10
作者
Flores, Jose M. [1 ]
Bernie, Helen L. [1 ]
Miranda, Eduardo [1 ]
Nascimento, Bruno [1 ]
Schofield, Elizabeth [2 ]
Benfante, Nicole [1 ]
Carlsson, Sigrid [3 ,4 ]
Mulhall, John P. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Urol Serv, Sexual & Reprod Med Program, 16 E 60th St, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
Testosterone; PSA; Prostate Cancer; Testosterone De fi ciency; Hypogonadism; SERUM TESTOSTERONE; GLEASON SCORE; OLDER MEN; ANTIGEN; THERAPY; RISK; AGE; GRADE; HYPOGONADISM; ASSOCIATION;
D O I
10.1016/j.jsxm.2022.01.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate-specific antigen (PSA) secretion is a testosterone (T) dependent process. Published data suggest that a low T level is an independent predictor of higher-grade prostate cancer (PC). Aim: To evaluate the relationship between T and PSA in patients with PC. Methods: All men diagnosed with PC with a recorded pre-treatment total T level measurement were included in this analysis. We analyzed demographic, clinical, and pathological data. Patients were stratified according to pretreatment PSA levels: <2 ng/mL, 2-4 ng/mL, >4 ng/mL. Low T was defined as total T < 10.4 nmol/L (300 ng/dL), very low T < 6.9 nmol/L (200 ng/dL). Outcomes: T levels by PSA groups according to the PC pathology. Results: In this retrospective study, mean patient age was 61 years among 646 men. The distribution by PSA group was: 8% (<2), 17% (2-4), and 76% (>4). The mean T level across the entire cohort was 13 nmol/L (374 ng/dL). Overall, 30% had a T level < 10.4 nmol/L (300 ng/dL). The mean total T level by PSA group was: <2 ng/mL, 7 nmol/L (206 ng/dL); 2-4 ng/mL, 13 nmol/L (362 ng/dL); >4 ng/mL, 14 nmol/L (393 ng/dL), P <.001. PSA <4 ng/mL was a significant predictor of low T in men with PC GS >= 8. PSA <2 ng/mL was a significant predictor of very low T independent of the PC pathology. Clinical Implications: These findings suggest that clinicians should consider measuring T levels when a patient diagnosed with PC GS =8 and PSA level <4 ng/mL, and for each patient with PSA level <2 ng/mL independent of the PC pathology. Strengths & Limitations: Our study has several strengths including (i) inclusion of a large population of men, (ii) use of a database which is audited and reviewed for accuracy annually, and (iii) use of an accurate T assay (LCMS). Nonetheless, there are limitations: (i) the subjects of the study are from a single institution, and (ii) we did not measure free T levels. Conclusion: In men with PC with GS >= 8, PSA level <4 ng/mL predicts low T. PSA <2 ng/mL predicts very low T independent of the PC pathology. Copyright (C)22, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:471 / 478
页数:8
相关论文
共 43 条
[1]   Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? [J].
Abdollah, F. ;
Briganti, A. ;
Suardi, N. ;
Gallina, A. ;
Capitanio, U. ;
Salonia, A. ;
Cestari, A. ;
Guazzoni, G. ;
Rigatti, P. ;
Montorsi, F. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2011, 14 (01) :74-78
[2]   Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy [J].
Ahlering, Thomas E. ;
Huynh, Linda My ;
Towe, Maxwell ;
See, Kaelyn ;
Tran, Joshua ;
Osann, Kathryn ;
el Khatib, Farouk M. ;
Yafi, Faysal A. .
BJU INTERNATIONAL, 2020, 126 (01) :91-96
[3]   Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study [J].
Araujo, AB ;
O'Donnell, AB ;
Brambilla, DJ ;
Simpson, WB ;
Longcope, C ;
Matsumoto, AM ;
McKinlay, JB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (12) :5920-5926
[4]   COMBINED LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY .3. APPLICATIONS OF THERMOSPRAY [J].
ARPINO, P .
MASS SPECTROMETRY REVIEWS, 1992, 11 (01) :3-40
[5]   Biology of prostate-specific antigen [J].
Balk, SP ;
Ko, YJ ;
Bubley, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :383-391
[6]   SCREENING FOR PROSTATIC-CARCINOMA WITH PROSTATE SPECIFIC ANTIGEN [J].
BRAWER, MK ;
CHETNER, MP ;
BEATIE, J ;
BUCHNER, DM ;
VESSELLA, RL ;
LANGE, PH .
JOURNAL OF UROLOGY, 1992, 147 (03) :841-845
[7]   American Urological Association (AUA) Guideline on prostate cancer detection: process and rationale [J].
Carter, H. Ballentine .
BJU INTERNATIONAL, 2013, 112 (05) :543-547
[8]   History of the discovery and clinical translation of prostate-specific antigen [J].
Catalona, William J. .
ASIAN JOURNAL OF UROLOGY, 2014, 1 (01) :12-14
[9]   MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
DODDS, KM ;
COPLEN, DE ;
YUAN, JJJ ;
PETROS, JA ;
ANDRIOLE, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161
[10]   Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial [J].
Cunningham, Glenn R. ;
Ellenberg, Susan S. ;
Bhasin, Shalender ;
Matsumoto, Alvin M. ;
Parsons, J. Kellogg ;
Preston, Peter ;
Cauley, Jane A. ;
Gill, Thomas M. ;
Swerdloff, Ronald S. ;
Wang, Christina ;
Ensrud, Kristine E. ;
Lewis, Cora E. ;
Pahor, Marco ;
Crandall, Jill P. ;
Molitch, Mark E. ;
Cifelli, Denise ;
Basaria, Shehzad ;
Diem, Susan J. ;
Stephens-Shields, Alisa J. ;
Hou, Xiaoling ;
Snyder, Peter J. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (12) :6238-6246